Amphista Therapeutics begins first human trial of AMX-883 BRD9 degrader in acute myeloid leukemia
Amphista begins its 54-patient AMX-883 Phase 1 trial in AML and high-risk MDS. Examine the novel BRD9 mechanism, safety tests and next milestones.
Pharma & Biotech
Pharma & Biotech
I2Pure’s iodine formulations kill over 99.9% of major pathogens in seconds, but can hospitals use them?
I2Pure molecular iodine kills major drug-resistant pathogens within seconds in lab tests. Examine efficacy, staining and hospital adoption barriers.
Pharma & Biotech
Keenova’s TERLIVAZ shows kidney response in transplant-ineligible patients as new CONFIRM analysis emerges
Keenova's TERLIVAZ analysis examines kidney recovery in transplant-ineligible HRS-AKI patients as respiratory safety and survival remain key concerns.
Pharma & Biotech
Tortugas Neuroscience reports positive Phase 2b results for schizophrenia treatment
Obuprazine met the primary endpoint across three dose groups in a 363-patient Phase 2b schizophrenia study, with the strongest dose producing a 16.7-point placebo-adjusted PANSS improvement. Early symptom responses and low discontinuation rates support further development, but longer-term safety and comparative efficacy remain unproven.
Pharma & Biotech
Did Rubedo’s experimental drug really make skin two years younger? Phase 1b data reveal a surprising signal
Rubedo's RLS-1496 reduces measured skin epigenetic age by 2.1 years in early research, but clinical benefits remain to be proven.
Pharma & Biotech
Stoke Therapeutics boosts a protein linked to inherited blindness, but can STK-002 save vision?
Stoke Therapeutics reports STK-002 OPA1 protein gains as Phase 1 OSPREY advances. Examine the evidence, safety questions and 2027 readout.
Pharma & Biotech
Catalent is entering unit-dose OTC gels with Mantra. Can medicine in a pouch challenge pills?
Catalent will manufacture Mantra's single-serve OTC gels for sleep, pain and menstrual relief. See what the deal means for drug delivery and supply.
Pharma & Biotech
Can TG Therapeutics establish BRIUMVI superiority without a head-to-head clinical trial?
A peer-reviewed five-year indirect comparison associates BRIUMVI with lower modeled disability progression risk than ocrelizumab and ofatumumab. The findings support TG Therapeutics' commercial evidence strategy but cannot establish head-to-head superiority.
Pharma & Biotech
LIVMARLI cuts bile acids 70% in Phase 3. Can Mirum turn its biliary atresia breakthrough into FDA approval?
Mirum's LIVMARLI meets its Phase 3 itch endpoint and cuts bile acids, supporting a planned 2027 FDA filing for rare liver diseases.
Pharma & Biotech
ANB033 shows significant protection against gluten damage in First Tracks Biotherapeutics’ celiac disease trial
Explore how First Tracks Biotherapeutics' ANB033 reduced gluten-induced intestinal damage and symptoms in a Phase 1b celiac disease trial.